The Cooper Companies, Inc. (NASDAQ:COO) Receives Average Recommendation of “Moderate Buy” from Brokerages

The Cooper Companies, Inc. (NASDAQ:COO) has been given an average recommendation of “Moderate Buy” by the ten analysts that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $110.25.

COO has been the subject of several research analyst reports. JPMorgan Chase & Co. cut their price objective on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, March 7th. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a research note on Thursday, March 13th. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Citigroup cut their target price on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Finally, Wells Fargo & Company increased their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, December 6th.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $84.07 on Tuesday. The stock’s 50-day simple moving average is $89.90 and its two-hundred day simple moving average is $97.88. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $16.81 billion, a P/E ratio of 43.11, a P/E/G ratio of 2.25 and a beta of 1.02. Cooper Companies has a twelve month low of $77.05 and a twelve month high of $112.38.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. As a group, equities analysts anticipate that Cooper Companies will post 3.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Byrne Asset Management LLC purchased a new stake in shares of Cooper Companies in the fourth quarter valued at $33,000. OFI Invest Asset Management purchased a new position in shares of Cooper Companies in the 4th quarter worth $34,000. New Age Alpha Advisors LLC purchased a new stake in shares of Cooper Companies during the 4th quarter worth about $38,000. Brown Brothers Harriman & Co. increased its position in shares of Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares in the last quarter. Finally, Covestor Ltd raised its position in Cooper Companies by 35.5% in the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock valued at $42,000 after purchasing an additional 120 shares during the period. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.